Provides Regulatory Update on mB s TKA System and Clinical Trial Preparation in India

Monogram Technologies

Provides Regulatory Update on mB s TKA System and Clinical Trial Preparation in India

Company has Completed

all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR)

Meeting and Clinical Trial Training Held at the Shalby Hospital in Ahmedabad, India

February 25, 2025 - Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven

robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update regarding its

510(k) premarket filing submission to the U.S. Food and Drug Administration ("FDA") for the Company's mB s TKA System. The

Company has completed all supplemental testing and submitted its formal response to the U.S. Food and Drug Administration (FDA) regarding

the Additional Information Request (AIR) received on September 30, 2024. The Company does not currently anticipate further requests

for information from the agency. Assuming a favorable decision by the FDA following receipt of the AIR, the next communication from them

is anticipated to be a clearance decision for the mB s Total Knee Arthroplasty (TKA) System. If granted, that would enable

commercialization and sales of the TKA system in the United States.

In August 2024, Monogram announced a strategic

collaboration with Shalby Limited (NSE: SHALBY) ("Shalby"), a global multi-specialty hospital chain and one of India's leading

orthopedic hospital groups, to conduct a multicenter clinical trial to evaluate the safety and effectiveness of the mB s TKA System.

In January 2025, the Company shipped a robot to support clinical trial training. The robot was successfully shipped as planned, and

an Investigator Meeting was conducted at a Shalby Hospital in Ahmedabad, India, from January 31 to February 1, 2025. The

meeting was organized by Reliance Life Sciences, a subsidiary of Reliance Industries, and attended by principal investigators, multiple

surgeons, and staff. The purpose of the meeting was to review study protocols, regulatory requirements, and operational procedures.

Reliance Life Sciences, a Reliance Group company-one

of India's largest private sector companies-is responsible for managing the regulatory submission and communications for the

clinical trial in India. As the regulatory sponsor, Reliance Life Sciences is overseeing the submission process and engagement with India's

regulatory authorities. Monogram has submitted its system for regulatory clearance to run the clinical trial and will provide updates

as they occur. While regulatory timelines can be variable, the Company remains confident in its submission and the strength of its strategic

partnerships with Reliance Life Sciences and Shalby to support the process.

"The Investigator Meeting was a successful

milestone in the preparation for Monogram's clinical trial," said Dr. Ajaykumar Yadav, Associate Vice President and

Group Head of Clinical Research at Reliance Life Sciences. "Bringing together key stakeholders, the meeting provided an opportunity

for in-depth discussions on study protocols and a demonstration of the mB s technology, reinforcing the collaborative approach

to this clinical trial. Monogram has submitted a strong and comprehensive application, and we continue to support the regulatory process

as expected. Reliance Life Sciences remains committed to advancing innovation in healthcare and looks forward to contributing to the

successful execution of this study."

Monogram team in Ahmedabad, India,

with various stakeholders for clinical trial Investigator Meeting from Jan 31 to Feb 1, 2025.

Monogram continues to refine and enhance its

next-gen technology in parallel with its regulatory and clinical trial preparations. The most significant advancement has been to the

cutting system, which has facilitated an approximately 300% increase in feed rate. A video demonstrating these next-gen improvements

Dr. Douglas Unis, Monogram's Chief Medical Officer, commented,

"The latest advancements in Monogram's robotic system are a game changer. The new cutting system enables cutting speeds that

are becoming competitive with manual surgery while maintaining the accuracy and functionality expected from robotic-assisted procedures.

The performance is truly remarkable for a completely hands-free, unconstrained autonomous system. With these improvements, we are on track

to deliver one of the most impressive robotic solutions on the market today."

The Company remains focused on developing a multi-application robotic system that is time-competitive with manual surgery without compromising

accuracy or safety. Monogram continues to refine its technology to improve system performance and usability as it progresses toward commercialization.

The Company believes its approach to active robotic cutting offers a unique value proposition and remains committed to innovation in orthopedic

"We have completed all proposed testing

with what we view to be favorable results and we remain focused on developing a robotic platform that surgeons will want to use,"

said Ben Sexson, CEO. "Our research shows that safety and uncompromised speed are the top priorities for surgeons. We have always

believed that an autonomous system could be optimized to be competitive with manual surgical times. I feel confident we are starting to

get there. Like our shareholders, we are eager to bring this vision to the operating room.

We have built a system that we believe has

the potential to disrupt the market. Our thesis is that fast, accurate, unconstrained autonomous cutting, eventually in many clinical

applications, will help drive continued adoption of robotics. Our technology has undergone rigorous and extensive testing, and we have

made every effort to try and ensure our system meets the highest standards.

What we have accomplished-with fewer

than 30 full-time employees-is a testament to the dedication and expertise of our team. I could not be prouder of what our small

and highly dedicated team has achieved."

About Monogram Technologies Inc.

Monogram Technologies (NASDAQ: MGRM) is an AI-driven

robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution

architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation

Monograms mB s precision robotic surgical

system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants.

The goal is well balanced, better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic

surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous

instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mB s

with mVision navigation are also being explored.

Monogram has obtained FDA clearance for mPress

implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can

market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances.

The Company believes that its mB s precision

robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for

patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may

be other clinical and commercial applications for its navigated mB s precision robot and mVision navigation.

To learn more, visit www.monogramtechnologies.com.

Forward-Looking Statements

This press release may contain "forward-looking

statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical

facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results

and involve a number of risks and uncertainties.. Forward-looking statements, other than statements of historical fact, are highly likely

to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control,

and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of

future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result

of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes

no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Executive Vice President

Direct: 949-491-8235